ArticleCancer research2007
Identification of novel amplification gene targets in mouse and human breast cancer at a syntenic cluster mapping to mouse ch8A1 and human ch13q34.
Article in Cancer research, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 53 citations in OpenAlex.
- Comprehensive Analysis Reveals the Potential Roles of Transcription Factor Dp-1 in Lung Adenocarcinoma.World journal of oncology · 2023Article
- CUL4The American journal of pathology · 2021Article
- Diarylpentanoid (1,5-bis(4-hydroxy-3-methoxyphenyl)-1,4-pentadiene-3-one) (MS13) Exhibits Anti-proliferative, Apoptosis Induction and Anti-migration Properties on Androgen-independent Human Prostate Cancer by Targeting Cell Cycle-Apoptosis and PI3K Signalling Pathways.Frontiers in pharmacology · 2021Article
- AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations.International journal of molecular sciences · 2020Review
- Molecular and Cellular Factors Associated with Racial Disparity in Breast Cancer.International journal of molecular sciences · 2020Review
- Targeting Gas6/TAM in cancer cells and tumor microenvironment.Molecular cancer · 2018Review
- Identification of epigenetic modulators in human breast cancer by integrated analysis of DNA methylation and RNA-Seq data.Epigenetics · 2018Article
- Suppression of CUL4A attenuates TGF-β1-induced epithelial-to-mesenchymal transition in breast cancer cells.International journal of molecular medicine · 2017Article
- TAM receptors Tyro3 and Mer as novel targets in colorectal cancer.Oncotarget · 2016Article
- Knockdown of cullin 4A inhibits growth and increases chemosensitivity in lung cancer cells.Journal of cellular and molecular medicine · 2016Article
- Identification of disease-associated pathways in pancreatic cancer by integrating genome-wide association study and gene expression data.Oncology letters · 2016Article
- Distinct and overlapping functions of the cullin E3 ligase scaffolding proteins CUL4A and CUL4B.Gene · 2015Review
- Cul4A overexpression associated with Gli1 expression in malignant pleural mesothelioma.Journal of cellular and molecular medicine · 2015Article
- Article
- Identification of sample-specific regulations using integrative network level analysis.BMC cancer · 2015Article
- Article
- Lung tumourigenesis in a conditional Cul4A transgenic mouse model.The Journal of pathology · 2014Article
- CUL4A contributes to the biology of basal-like breast tumors through modulation of cell growth and antitumor immune response.Oncotarget · 2014Article
- Oncogenic function of SCCRO5/DCUN1D5 requires its Neddylation E3 activity and nuclear localization.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
- CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression.Cancer research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Serial analysis of gene expression from aggressive mammary tumors derived from transplantable p53 null mouse mammary outgrowth lines revealed significant up-regulation of Tfdp1 (transcription factor Dp1), Lamp1 (lysosomal membrane glycoprotein 1) and Gas6 (growth arrest specific 6) transcripts. All of these genes belong to the same linkage cluster, mapping to mouse chromosome band 8A1. BAC-array comparative genomic hybridization and fluorescence in situ hybridization analyses revealed genomic amplification at mouse region ch8A1.1. The minimal region of amplification contained genes Cul4a, Lamp1, Tfdp1, and Gas6, highly overexpressed in the p53 null mammary outgrowth lines at preneoplastic stages, and in all its derived tumors. The same amplification was also observed in spontaneous p53 null mammary tumors. Interestingly, this region is homologous to human chromosome 13q34, and some of the same genes were previously observed amplified in human carcinomas. Thus, we further investigated the occurrence and frequency of gene amplification affecting genes mapping to ch13q34 in human breast cancer. TFDP1 showed the highest frequency of amplification affecting 31% of 74 breast carcinomas analyzed. Statistically significant positive correlation was observed for the amplification of CUL4A, LAMP1, TFDP1, and GAS6 genes (P < 0.001). Meta-analysis of publicly available gene expression data sets showed a strong association between the high expression of TFDP1 and decreased overall survival (P = 0.00004), relapse-free survival (P = 0.0119), and metastasis-free interval (P = 0.0064). In conclusion, our findings suggest that CUL4A, LAMP1, TFDP1, and GAS6 are targets for overexpression and amplification in breast cancers. Therefore, overexpression of these genes and, in particular, TFDP1 might be of relevance in the development and/or progression in a significant subset of human breast carcinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.